COMP <GO>
BAX vs LLY // FORWARD P/E MULTIPLE
Baxter International Inc. (NYSE) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: BAX 5
— LLY 9
▲ FORWARD P/E MULTIPLE LEADER: BAX
LAST: $23.00 (-2.13%) • MKT CAP: $12.15B
forward-pe
18.0x
LAST: $1,417.54 (+3.19%) • MKT CAP: $1.33T
forward-pe
26.3x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (BAX VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | BAX | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 30.10% | 83.64% | -53.54 | LLY | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -2.40% | 32.36% | -34.76 | LLY | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 36.4x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 2.79% | 2.30% | +0.49 | BAX | /fcf-yield <GO> |
| Operating Margin | -2.70% | 40.21% | -42.91 | LLY | /operating-margins <GO> |
| Net Profit Margin | -8.50% | 31.90% | -40.40 | LLY | /net-margins <GO> |
| Revenue Growth (YoY) | 5.70% | 45.51% | -39.81 | LLY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 2.86% | 0.49% | +2.37 | BAX | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.22 | 9.29 | -7.07 | LLY | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 9/9 | -3.00 | LLY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.70% | 6.77% | -0.07 | BAX | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 37.8 | 77.9 | -40.13 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.95 | 0.51 | +0.44 | BAX | /macro-sensitivity <GO> |
| Forward P/E Multiple ACTIVE | 18.0x | 26.3x | -8.25 | BAX | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $12.15B | $1.33T | -$1.32T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | BAX REV | LLY REV | BAX GROSS % | LLY GROSS % | BAX FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $11.24B | $65.18B | 30.1% | 83.0% | $339.0M | $16.81B |
| FY 2024 | $10.64B | $45.04B | 37.5% | 81.3% | $540.4M | $8.82B |
| FY 2023 | $10.36B | $34.12B | 44.0% | 79.3% | $1.26B | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
BAX // BETA 0.95
LLY // BETA 0.51